Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial (Q28211411)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial	scientific article

Statements

scholarly article

0 references

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial (English)

0 references

randomized controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michael Doherty

object named as

Michael Doherty

5

0 references

author name string

Thomas J Schnitzer

1

0 references

Gerd R Burmester

2

0 references

Eduardo Mysler

3

0 references

Marc C Hochberg

4

0 references

Elena Ehrsam

6

0 references

Xavier Gitton

7

0 references

Gerhard Krammer

8

0 references

Bernhard Mellein

9

0 references

Patrice Matchaba

10

0 references

Alberto Gimona

11

0 references

Christopher J Hawkey

12

0 references

language of work or name

0 references

publication date

August 2004

1 reference

0 references

364

0 references

665-74

0 references

9435

0 references

Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective cyclooxygenase-2 inhibitors: similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Problems associated with the clinical use of proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916893-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(04)16893-1

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28211411&oldid=1516220817"